Phase 3 Alopecia Areata Trial, Recruiting NCT07617597 Sponsor: Sun Pharma Japan Limited Condition: Alopecia Areata
Back to Alopecia Areata

Phase 3 Alopecia Areata Trial, Recruiting

NCT07617597
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have agreed to take part and signed a consent form.
  • You are Japanese, aged between 18 and 65 years old at the time of signing the consent form, and have severe alopecia areata (significant hair loss condition).
  • You have been officially diagnosed with alopecia areata and your current episode of scalp hair loss has been ongoing for at least 6 months.
  • Your hair loss has been measured using a specific scoring system (called a SALT score) and the result is 50 or higher at both your initial screening visit and your baseline visit before the trial begins (confirm with trial site).

Who may not be able to join:

  • You have taken medications that suppress the immune system — including a type of drug called JAK inhibitors — within the last 4 months.
  • You have received a type of treatment called biologics (medicines made from living cells) within the last 6 months.
  • Your blood tests at screening showed a positive result for hepatitis B, hepatitis C, or HIV.
  • You have a history of active tuberculosis (TB), a positive TB blood test at screening, or signs of TB-related changes seen on a chest X-ray.
  • Your screening blood tests showed significant problems with your blood, liver, or kidneys.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Sun Pharma Japan Limited
Registry
ClinicalTrials.gov
Start date
19 June 2026
Est. completion
1 February 2028

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Percentage of subjects achieving an absolute SALT score of 20 or less

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov